argenx vs BioMarin Pharmaceutical
argenx reported revenue of $4.2 billion in fiscal 2025, 1.3 times BioMarin Pharmaceutical's $3.2 billion in fiscal 2025. argenx's revenue grew 88.6% in its latest year, and BioMarin Pharmaceutical's grew 12.9%. argenx had an operating margin of 24.8%, against 12.7% at BioMarin Pharmaceutical. Free cash flow was $679 million at argenx and $725 million at BioMarin Pharmaceutical.
Side by side
| argenx | BioMarin Pharmaceutical | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $4.2B | $3.2B |
| Revenue growth | 88.6% | 12.9% |
| Revenue growth a year, last 5 years | 152.7% | 11.6% |
| Gross margin | 89.4% | 77.7% |
| Operating margin | 24.8% | 12.7% |
| Net margin | 30.4% | 10.8% |
| Free cash flow | $679M | $725M |
| Free cash flow margin | 16.0% | 22.5% |
| Return on capital | — | 5.8% |
| Net debt to EBITDA | — | −2.0x |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 1.3% | 0.3% |
| Last close | $942.04 | $61.42 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | sold $4.6 million |
| Piotroski F-score | — | 5 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
argenxBioMarin Pharmaceutical
Operating margin
Percent of revenue
argenxBioMarin Pharmaceutical
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
argenxBioMarin Pharmaceutical
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the argenx and BioMarin Pharmaceutical pages.